TheEdgeResearch
Home / Stocks / COYA

Coya Therapeutics, Inc. (COYA)

NASDAQ Healthcare Biotechnology
$6.04 ▼ -0.58%
Market Cap
$109.9M
Sector
Healthcare
Industry
Biotechnology
Beta
0.62
52-Wk Range
3.71-7.75
CEO
Arun Swaminathan
Country
US
Currency
USD

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applicati…

Open full interactive analysis & DCF →